Brian Gallagher, Jr has left SR One after eight years as a partner, setting up a Boston office on the way, to join Abingworth.

Cancer biosimilar developer JHL Biotech raised an undisclosed sum in a Sanofi-backed round as it prepares to re-list on a stock exchange, this time choosing Hong Kong.

Lilly Asia Ventures and existing backer Alexandria Real Estate Equities helped the cancer immunotherapy developer add $80m to the $76m it closed last year.

The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.

Partly based on Columbia University research, Modis is advancing treatments for rare diseases caused by dysfunction in cellular mitochondria.

Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.

Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.

University of Rochester-affiliated VC fund Excell Partners has been selected to manage a state government-funded vehicle targeting local companies in sectors such as optics and life sciences.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The diabetes diagnosis technology developer harnessed Heritage Provider Network and Optum Ventures for its latest round.